Insider filing · AMLX
Justin B. Klee
Co-Chief Executive Officer
profile →
Amylyx Pharmaceuticals, Inc.
AMLX · Healthcare · 20 filings in 24 months
ticker →
Justin B. Klee sold $428K of Amylyx Pharmaceuticals (AMLX)
Executed Sep 30 2025, disclosed Oct 2 2025, 2 days later.
Value, as filed
$428K
29,775 sh × $14.37
Executed
Sep 30 2025
the trade date, as filed
Disclosed
Oct 2 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JKJustin B. Klee (Co-Chief Executive Officer) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Amylyx Pharmaceuticals, Inc. (AMLX). The largest single filing was $1.8M of AMLX (136,193 sh × $13.58, as filed), executed Jan 15.
The name
AMLXHealthcare · Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for ne…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Justin B. Klee in AMLX
AMLXSALE
Amylyx Pharmaceuticals, Inc.
$933K29,025 sh × $32.13
Exec Sep 10
Filed Sep 14 · 4:00 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. $424K
29,282 sh × $14.47
Exec Mar 2
Filed Mar 4 · 5:30 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. $228K
15,500 sh × $14.69
Exec Feb 2
Filed Feb 4 · 5:30 PM ET AMLXSALE Amylyx Pharmaceuticals, Inc. $1.8M
136,193 sh × $13.58
Exec Jan 15
Filed Jan 20 · 5:30 PM ET